Sodium-Glucose Cotransporters as Potential Therapeutic Targets in Patients With Type 1 Diabetes Mellitus: An Update on Phase 3 Clinical Trial Data.

Conclusions: Phase 3 trial data of SGLT inhibitors provide evidence for sustained efficacy in T1DM patients. Appropriate patient selection for therapy and routine monitoring are essential to minimize associated risks. PMID: 31226886 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31226886?dopt=Abstract

Source: The Annals of Pharmacotherapy - June 20, 2019 Category: Drugs & Pharmacology Authors: Patel K, Carbone A Tags: Ann Pharmacother Source Type: research